Viewing Study NCT06184204



Ignite Creation Date: 2024-05-06 @ 7:55 PM
Last Modification Date: 2024-10-26 @ 3:16 PM
Study NCT ID: NCT06184204
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2024-03-19
First Post: 2023-12-14

Brief Title: Observational StudySafetyEfficacy and Quality of Life of Patients With Atrial Fibrillation Treated With Trombix
Sponsor: Beker Laboratories
Organization: Beker Laboratories

Study Overview

Official Title: Prospective National Multicentric Observational Study to Evaluate the Safety Efficacy and Quality of Life of Patients With Atrial Fibrillation Treated With Trombix Rivaroxaban
Status: ACTIVE_NOT_RECRUITING
Status Verified Date: 2024-08
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: TROMBIXDZ
Brief Summary: The rational behind this observational study is to collect real life data about the use of Trombix Rivaroxaban among patients with atrial fibrillation in Algeria The aim is to evaluate the safety efficacy and quality of life
Detailed Description: Trombix Rivaroxaban is used for the treatment of patients with atrial fibrillation BEKER laboratories are conducting an observation study to evaluate its use among Algerian population in regards to its safety efficacy and the quality of life of patients after its use

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None